The biopharmaceutical industry makes a substantial impact on the health, well-being, and economic prosperity of the nation. The industry develops and manufactures life-changing therapies for patients and contributes significantly to the U.S. economy. Currently, the industry accounts for nearly $800B of total economic activity per year and directly employs more than 850,000 people in high-wage and high-value jobs.3 Finally, the industry aids in national security by producing products that address public health threats whether natural or man-made.
The NIIMBL Annual Report 2017-18
However, in recent years, the biopharmaceutical manufacturing industry has faced new challenges from a globalized biopharmaceutical industry.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) was created, in part, to continue domestic investment and innovation in this crucial industry sector. The establishment of NIIMBL represents a singular opportunity to coordinate national stakeholders and catalyze a multifaceted effort to assure that the U.S. will not only have best-in-the-world biopharmaceutical research and development (R&D), but also retain the value of manufacturing the medicines it discovers, thereby securing the domestic medicine supply, including the ability to respond to national health emergencies and national security challenges.
Through this unified commitment to manufacturing technology innovations and workforce development, NIIMBL promises to advance U.S. competitiveness in this globalized field by improving patient access to cutting-edge medical treatments, supporting economic development, and contributing to national security.
